The gene NCU03826 that was speculated to encode K-NMT in a patent application (Kang et al., 2013) did not result in a biosensor response that would indicate improved L-carnitine levels and the supplementation of lysine and methionine as precursors did not change this outcome (data not shown)
~ Genetic variants in these genes can impair energy production, especially under stress or fasting
These patients continue twice-weekly dosing long-term, often because they believe it is working better, even when objective outcomes (weight loss, A1c reduction) are identical to weekly dosing
Key differential aspects of the group of glucagon-like peptide-1 receptor agonist drugs There are several arGLP-1 s approved or under study for the use in DM2: exenatide (exenatide and exenatide LAR or weekly), liraglutide, lixisenatide, dulaglutide, semaglutide, albiglutide (withdrawn from the market), and efpeglenatide (in clinical development)